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Pseudomonas aeruginosa biofilm infections in the cystic fibrosis (CF) lung are highly resistant to current antimi-
crobial treatments and are associated with increased mortality rates. The existing models for such infections are
not able to reliably mimic the clinical biofilms observed. We aimed to further optimise an ex vivo pig lung (EVPL)
model for P. aeruginosa CF lung infection that can be used to increase understanding of chronic CF biofilm
infection. The EVPL model will facilitate discovery of novel infection prevention methods and treatments, and
enhanced exploration of biofilm architecture. We investigated purine metabolism and biofilm formation in the
model using transposon insertion mutants in P. aeruginosa PA14 for key genes: purD, gacA and pelA. Our results
demonstrate that EVPL recapitulates a key aspect of in vivo P. aeruginosa infection metabolism, and that the
pathogen forms a biofilm with a clinically realistic structure not seen in other in vitro studies. Two pathways
known to be required for in vivo biofilm infection - the Gac regulatory pathway and production of the Pel exo-
polysaccharide - are essential to the formation of this mature, structured biofilm on EVPL tissue. We propose the
high-throughput EVPL model as a validated biofilm platform to bridge the gap between in vitro work and CF lung
infection.Introduction
Biofilms are microbial aggregates that consist of bacterial cells and a
self-produced matrix primarily composed of proteins, lipids, poly-
saccharides and nucleic acids [1]. The biofilm matrix provides the mi-
crobial population with increased antibiotic tolerance and protection
against the host immune response [2]. The persistent, biofilm-associated,
lung infections that affect people with the genetic condition Cystic
Fibrosis (CF) are highly resistant to antibiotic treatment and, despite
being well studied, continue to have a large impact on health and life
expectancy. More than 70,000 people worldwide are believed to have CF,
though it is thought to be widely underdiagnosed across Asia as epide-
miological reports are largely derived from data collected in western
countries [3–5]. Despite the rising average life expectancy of people with
CF [6], it still has one of the highest mortality rates among human genetic
conditions [5].
CF lung infections are known to be polymicrobial [7]. However,
Pseudomonas aeruginosa is the most abundant CF pathogen in the UK. It is
estimated that 75% of adults with CF are either chronically or transiently
infected with P. aeruginosa during their lifetime [8,9]. By 5 years old
approximately 53% of children with CF are infected with P. aeruginosa(N.E. Harrington), E.Sweeney@w
orm 24 March 2020; Accepted 2
evier B.V. This is an open access a[10,11]. Detection of P. aeruginosa infection is associated with worsened
disease outcomes including rapid lung function decline and higher
mortality rates [12–14].
P. aeruginosa is able to switch from the initial acute stage of infection,
where virulence is high, infection is transient and biofilms are not formed
[15], to chronic biofilm infection. This chronic infection is characterised
by embedding of P. aeruginosa biofilm aggregates in the mucus plugs
typically found in the airways of people with CF [16]. Chronic infection is
traditionally difficult to replicate in vitro and so the ability to study
P. aeruginosa virulence, persistence and treatment response at this stage
of infection is limited. Once established, chronic P. aeruginosa infection is
almost impossible to eradicate, and there is a poor correlation between
antibiotic susceptibility testing and the clinical outcomes of antibiotic
treatment [17,18]. This is largely a result of altered resistance pheno-
types in in vivo biofilms compared with in vitro [19]. Without the
development of novel models to study clinically realistic, CF-associated
chronic biofilm infections in the laboratory, development of more
effective treatments to prevent or treat these infections will continue to
be hindered.
There are a number of models currently used to study P. aeruginosa in
mono- and polymicrobial CF biofilm infections. These include, but arearwick.ac.uk (E. Sweeney), F.Harrison@warwick.ac.uk (F. Harrison).
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Table 1
Description of the Pseudomonas aeruginosa PA14 transposon insertion mutants
used for our work [38,39]. Information for each gene is provided and the asso-
ciated CF infection phenotype following loss of gene function [23,40,41].
Mutant
ID
Active
Gene ID
Active
Gene
Name
Active Gene Description Predicted
Infection
Phenotype in
EVPL
31800 GID1896 leuB 3-isopropylmalate
dehydrogenase
No effect
23405 GID1574 metX Homoserine
O-acetyltransferase
No effect
29794 GID1301 purD Phosphoribosylamine–
glycine ligase
No effect
54630 GID3719 gacA Response regulator GacA Biofilm
maturation
defects
26187 GID86 pelA Conserved hypothetical
protein
Unable to form
biofilm
N.E. Harrington et al. Biofilm 2 (2020) 100024not limited to, artificial sputum media (ASM) [20–23], in vitro
surface-attached biofilm models [24] and murine models with cystic
fibrosis transmembrane conductance regulator mutations that mimic the
mutations causative of CF in humans [25]. Limitations with such model
systems have been identified. There is a distinct difference in the
P. aeruginosa transcriptomic profiles between isolates grown in ASM and
direct transcriptomic analysis of CF sputum samples. It has been shown
that P. aeruginosa grown in laboratory media, including ASM, demon-
strates upregulation of key genes involved in amino acid and carbohy-
drate biosynthesis, the TCA cycle and quorum sensing regulation, in
comparison to human infection [26]. These differences indicate that
although advancements have been made for laboratory media that more
closely reflects the CF lung environment, it is still missing key aspects of
chronic infection such as metabolism.
It is also important to consider the structure of P. aeruginosa biofilms.
While this is hard to quantify, there are some distinct qualitative differ-
ences in the structure of biofilms grown in different in vitro platforms. For
example the dense, homogenous mass of cells and matrix seen in
microtitre plates versus the “mushroom” structures and open channels
observed in flow cells [27,28]. Comparison of these systems with in vivo
biofilms highlights further differences in structure. In particular, lung
biopsies of people with CF reveals biofilms suspended in bronchial mucus
with a ‘sponge’-like appearance. This mass of bacterial cells is punctuated
by gaps which may be filled with mucus, alginate or lung fluid [16,29,
30]. Hence, it is likely in vitro biofilms do not accurately mimic CF bio-
films or the aspects of infection that are structure dependent, such as
nutrient gradients in the biofilm matrix and resultant pockets of dormant
cells, which affect quorum sensing [2]. In addition, mouse models are
also unable to reliably mimic the P. aeruginosa infections that occur in
people with CF [31]. The airway secretions from CF mice have been
shown to be very different from human airway secretions [32], which
could explain the significant differences in P. aeruginosa transcriptome
that have found between mouse and human CF infection [26].
We previously published brief details of a novel ex vivo pig lung
(EVPL) model for P. aeruginosa biofilm infection of CF bronchioles. The
model combines one formulation of ASM with sections of porcine bron-
chiole [33]. The EVPL bronchiolar tissue demonstrated potential in
recapitulating clinically relevant chronic infection [33,34]. In compari-
son to more commonly used model organisms, including rats and mice,
pig lungs demonstrate closer similarity to human lungs. The two are
similar in their metabolic composition and overall physiology, anatomy
and immunology [32,35]. The lungs used for the model are obtained
from pigs slaughtered for meat, thus the EVPLmodel offers a replacement
for live animal (rodent) infection models, which is clinically realistic,
economical and ethical.
Here, we provide detailed validation of EVPL as a model for chronic
P. aeruginosa biofilm infection in CF. We have built on our previous work
to demonstrate that the model is able to successfully mimic clinically
relevant aspects of in vivo CF P. aeruginosa metabolism and biofilm for-
mation. We show key pathways required for CF P. aeruginosa biofilm
formation and maturation in vivo are similarly essential in EVPL. Our
findings highlight the importance of visualising biofilms in order to un-
derstand chronic infection in a way that in vitro models of bacterial
growth cannot achieve. We have also described the antibiotic tolerance
of P. aeruginosa CF isolates grown as biofilms in this model [36]. EVPL
has the potential to provide a platform to aid in the development of novel
drugs and treatment regimens, which can be used to target the growing
incidence of highly antibiotic-tolerant biofilms in the unique environ-
ment of CF lungs.
Materials and methods
Bacterial strains
Two isolates of P. aeruginosa (SED42, SED43), from a chronically-
colonised person with CF, were used as example clinical isolates.2These strains have previously been phenotypically characterised [37].
P. aeruginosa PA14 transposon insertion mutant strains (Table 1) and
the isogenic wild type (WT) used in this work were obtained from the
confirmed PA14 Non-Redundant Transposon Insertion Mutant Set [38,
39]. The transposon’s presence in the correct locus of the putative
PA14 mutants for leuB, purD, gacA and pelA was confirmed by arbitrary
PCR and Sanger sequencing [38,39]. Auxotrophy of the leuB and
purD mutants was confirmed by absence of growth in Agrobacterium
(AB) medium þ citrate and AB þ glucose minimal media (data not
shown). No sequence was obtained from three repeated PCRs for the
metX mutant hence locus-specific primers for metX were designed (50-
ATCGGGTCCTCACACGCTG-30 and 50-TCCGACCCTGAGTTCCTCG-30).
PCR and gel electrophoresis confirmed amplification of a fragment in the
putative metX mutant of ~1.5 kb. This is consistent with the presence of
the transposon (994 bp); the expected fragment in the absence of a
transposon is ~500 bp.
Artificial sputum media
The first artificial sputum medium (ASM) version, ASM1, was pre-
pared following a published recipe, also referred to as SCFM [22]. The
second ASM version: ASM2, is a slightly modified version of ASM1 and
was similarly prepared following a published method, also referred to as
SCFM2 [23]. For instances where glucose was removed from these rec-
ipes, it was substituted with an equivalent volume of deionised water.
In vitro P. aeruginosa growth and biofilm formation in ASM
Colonies of PA14, SED42 and SED43 were taken from Luria-Bertani
(LB) agar plates (Melford) and grown overnight at 37 C. Colonies
were used to inoculate replicate 100 μl aliquots of ASM1 or ASM2,3 μM
glucose, in a 96-well microplate with a peg lid (Innovotech), n ¼ 4 per
growth condition. Cultures were incubated at 37 C for 24 h. Growth of
planktonic fractions of the populations was assessed by briefly shaking
the well plate then reading absorbance at 600 nm using a Tecan Spark
10M plate reader. Biofilm formation on pegs was quantified using a
crystal violet assay [42]. Briefly, pegs were rinsed with 150 μl
phosphate-buffered saline (PBS) in a fresh 96-well plate to remove
loosely-adhering cells. The peg lid was then transferred to a further
96-well plate with 150 μl 0.1% (w/v) crystal violet (Vickers Laboratories)
per well. It was incubated at room temperature for 15 min and the pegs
rinsed twice in PBS as above, before drying in a laminar flow hood for 30
min. The pegs were transferred to another 96-well plate containing 150
μl 95% (v/v) ethanol per well to solubilise the crystal violet. Absorbance
of the solubilised crystal violet was read at 590 nm in a Tecan Spark 10M.
The relative allocation of bacterial cells to the biofilm per well was
calculated by dividing A590nm of crystal violet by A600nm of corresponding
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In vitro growth of P. aeruginosa metabolic mutants
Cultures were grown for 6 h in LB at 37 C. Bacterial cells were
washed and starved in PBS for 2 h, then resuspended in ASM1 or ASM2.
One set of ASM cultures were left as per the original method, and the
other supplemented with either 20 μg ml1 leucine, 20 μg ml1 methi-
onine or 30 μg ml1 each of guanine, adenine, xanthine and hypoxan-
thine as relevant for each mutant. Purines had to be dissolved in NaOH,
so the comparative original ASM was supplemented with an equivalent
amount of NaOH. Subsequently, 150 μl of each resuspended culture was
transferred to a 96-well plate and grown for a further 24 h at 37 C in a
Tecan Spark 10M. Every 20 min, the plate was shaken for 5 s and the
absorbance read at 600 nm.
EVPL dissection and infection
EVPL was prepared as previously described [33]. Briefly, porcine
lungs were obtained from a local butcher (Quigley and Sons, Cubbington)
and dissected on the day of delivery under sterile conditions. The pleura
of the ventral surface was heat sterilised using a hot pallet knife. A sterile
razor blade was then used to make an incision in the lung, exposing the
bronchiole. A section of the bronchiole was extracted and the exterior
alveolar tissue removed using dissection scissors. Bronchiolar sections
were washed once in a 1:1 mix of Dulbecco’s modified Eagle medium
(DMEM) and RPMI 1640 supplemented with 50 μg ml1 ampicillin
(Sigma-Aldrich) then cut into ~5 mm wide longitudinal strips. The
bronchiolar strips were placed in a second 1:1 DMEM, RPMI 1640 þ 50
μg ml1 ampicillin wash and cut into squares (~5  5 mm). The tissue
squares were washed for a third time in 1:1 DMEM, RPMI 1640 þ 50 μg
ml1 ampicillin. Bronchiolar pieces were then further washed in ASM,
UV sterilised for 5 min and transferred to individual wells of a 24-well
plate containing 400 μl ASM (þ20 μg ml1 ampicillin) solidified with
0.8% (w/v) agarose per well.
A sterile 29G hypodermic needle (Becton Dickinson Medical) was
touched to the surface of a P. aeruginosa colony grown on LB agar over-
night at 37 C and used to pierce an individual piece of bronchiolar tis-
sue. Uninfected control tissue sections were mock inoculated with a
fresh, sterile needle. Following infection of all tissue pieces, 500 μl of
ASM þ20 μg ml1 ampicillin was added to each well. Tissue was incu-
bated at 37 C with a Breathe-Easier® membrane (Diversified Biotech)
for the desired length of time.
EVPL biofilm recovery and assessment of bacterial load
Bronchiolar tissue pieces were removed from the 24-well plate
following incubation, and each briefly washed in 500 μl PBS in a fresh 24-
well plate. Tissue pieces were then transferred into sterile homogenisa-
tion tubes (Fisherbrand) containing eighteen 2.38 mm metal beads
(Fisherbrand) and 1 ml PBS. Tissue was bead beaten in a FastPrep-24 5G
(MP Biomedicals) for 40 s at 4 m s1 to recover the bacteria and virulence
factors from the tissue-associated biofilm. To determine the bacterial
load, the homogenate was serially diluted in PBS and plated on LB agar.
Plates were incubated overnight at 37 C and colony counts used to
calculate colony forming units (CFU) per tissue piece.
Determination of P. aeruginosa virulence factor production in EVPL biofilms
To quantify virulence factors produced by the P. aeruginosa biofilm
population, the homogenate was diluted 1:4 in PBS to obtain a sufficient
volume for further experiments. The diluted homogenate was passed
through a 0.2 μm filter to remove bacterial cells and tissue debris.
To assay the amount of the siderophores pyoverdine and pyochelin
present in homogenates, 100 μl aliquots of diluted sterile homogenate
were transferred to a black 96-well plate. Fluorescence was measured3with excitation/emission of 40020/46020 nm for pyoverdine [43]
and 36035/46020 nm for pyochelin [44] in a Tecan Spark 10M.
To measure total protease, 100 μl of diluted sterile homogenate was
mixed with 5 mg azocasein (Sigma-Aldrich) dissolved in 900 μl 100 mM
Tris-HCl þ 1 mM CaCl2. The reaction mixture was incubated with 170
rpm shaking for 2 h at 37 C, then stopped by the addition of 100 μl 120
mM EDTA. The mixture was centrifuged at 13,000 rpm for 1 min and the
absorbance of the supernatant read at 400 nm.
The amount of two quorum sensing (QS) signals in the diluted sterile
homogenate was assayed using Escherichia coli biosensors [45]. Expres-
sion of a luxCDABE reporter in response to either 3-oxo-C12-HSL or
C4-HSL was measured as relative light units (RLU) for E. coli strains
carrying the reporter plasmids pSB1075 or pSB406 respectively.
Extracellular DNA detection in EVPL biofilms
Following 2 d and 7 d post-infection (PI), homogenate from EVPL
cultures of PA14 and SED43 and uninfected control tissue were centri-
fuged at 13,000 rpm for 1 min (n ¼ 3). The pellet was run through a
Promega Wizard® Genomic DNA extraction kit. Recovered DNA was
eluted in 50 μl sterile water and 10 μl of the eluate was loaded onto a
0.7% (w/v) agarose þ SYBR™ Safe stain (Invitrogen) gel. Following
electrophoresis, the resulting gel was visualised under blue light.
Crystal violet assay on EVPL biofilms
Infected and uninfected control bronchiolar tissue pieces were placed
in a 24-well plate with 500 μl PBS per well. The plate was briefly shaken
to remove any loosely-adhering P. aeruginosa cells from the tissue. Tissue
pieces were then moved to another 24-well plate with 500 μl 0.1% (v/v)
crystal violet per well, and incubated at room temperature for 15 min
with 170 rpm shaking. Tissue sections were transferred into a fresh 24-
well plate and the crystal violet treatment and incubation was
repeated. The tissue was then transferred to a further 24-well plate and
left to dry in a laminar flow hood for 30 min. The tissue and biofilm
bound crystal violet was solubilised in 500 μl 95% (v/v) ethanol and
incubated at room temperature for 15 min with 170 rpm shaking. The
tissue was removed from the wells and absorbance read at 590 nm in a
Tecan Spark 10M.
Congo red binding assay on EVPL biofilms
A Congo red binding assay to measure exopolysaccharide Pel pro-
duction was tested and adapted [46] for use with the EVPL model.
Infected EVPL bronchiolar tissue pieces were placed in individual 2 ml
Eppendorf tubes containing 1 ml of 2 mg ml1 Congo red (Vickers Lab-
oratories Ltd., UK) and uninfected tissue pieces used as negative assay
controls. Tubes were incubated for 90 min at 37 C with 170 rpm
shaking. Following incubation, the samples were centrifuged at 13,000
rpm for 5 min and the supernatant transferred to a transparent 96-well
plate. Each supernatant was diluted 1 in 10 in PBS to a final volume of
200 μl to be within the limit of detection. The absorbance was read at
490 nm in a Tecan Spark 10M. The bound Congo red absorbance was
determined by subtracting the A490nm of the infected tissue sample from
the mean average uninfected tissue A490nm.
Hematoxylin & eosin staining
P. aeruginosa infected EVPL tissue pieces and uninfected control tissue
were fixed in 10% (v/v) neutral buffered formalin (VWR Chemicals). The
tissue samples were sent to the University of Manchester’s Histology Core
Facility for paraffin wax embedding, sectioning and mounting. Mounted
tissue sections were de-paraffinized in xylene for 20 min. To re-hydrate
the tissue, slides were transferred to 95% (v/v) ethanol followed by
70% (v/v) ethanol. Any residual ethanol was removed by washing slides
in distilled water. Samples were stained in Mayer’s hemalum solution
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2 tsp sodium carbonate). Samples were counterstained in eosin Y solution
(Merck Millipore) for then dehydrated by dipping the slides in 95% (v/v)
ethanol. Samples were transferred to fresh 95% (v/v) ethanol then placed
in 100% (v/v) ethanol. The samples were then placed in xylene. The
samples were mounted using DPXmounting fluid and images taken using
a Zeiss Axio Scope. A1 light microscope with the Zeiss Axiocam Erc 5s
and Zeiss Zen 2.3 pro software.
Gram staining
P. aeruginosa infected EVPL tissue pieces, plus uninfected controls,
were fixed and paraffin-embedded as described above for H& E staining.
The tissue sections were de-paraffinized in xylene. Samples were re-
hydrated in 100% (v/v) ethanol for then moved to fresh 100% (v/v)
ethanol. Slides were placed in 95% (v/v) isopropanol then 70% (v/v)
isopropanol. Residual alcohol was removed by washing slides in distilled
water. Crystal violet (Pro-Lab Diagnostics) was applied to the samples
and rinsed with water, then iodine (Pro-Lab Diagnostics) was applied.
The iodine was then rinsed from the samples using tap water and acetone
added for decolourisation. Tap water was used to rinse off the acetone
and 1% (v/v) neutral red (Pro-Lab Diagnostics) applied to counterstain.
The slides were again rinsed with tap water and blotted dry with filter
paper. The samples were dehydrated in 100% (v/v) isopropanol then
placed in two fresh changes of 100% (v/v) xylene. Samples were
mounted using DPX mounting fluid and images taken using a Zeiss Axio
Scope. A1 light microscope with the Zeiss Axiocam Erc 5s and Zeiss Zen
2.3 pro software.
Alcian blue staining
EVPL tissue pieces infected with P. aeruginosa, and uninfected tissue
negative controls, were fixed, paraffin-embedded, de-paraffinized and re-
hydrated as described for H & E staining. Slides were stained in 1%
Alcian blue solution (pH 2.5) (Sigma-Aldrich) then rinsed using distilled
water. The samples were counterstained in nuclear fast red solution (Alfa
Aesar) and rinsed briefly in distilled water. Tissue sections were dehy-
drated in increasing ethanol concentrations and finally placed in xylene,
as performed for H & E staining. Samples were mounted with DPX
mounting fluid and images were taken of stained tissue sections using a
Zeiss Axio Scope. A1 light microscope with the Zeiss Axiocam Erc 5s and
Zeiss Zen 2.3 pro software.
Statistical analysis
Data were analysed using either R v3.5.1 or RStudio (v1.2.1335 on
Mac OSMojave v10.14.6) [47], with P< 0.05 considered significant. The
car package [48] was used to conduct ANOVAs with type II SS when
missing values caused non-orthogonality (i.e. analyses of C4-HSL and
total protease). The multcomp package [49] was used for post-hoc com-
parisons. The FactoMineR package [50] was used for principal compo-
nents analysis. All raw data and R code used for analyses, including data
transformations used to meet model assumptions, are provided in the
Data Supplement.
Results
Simple and complex formulations of artificial CF sputum lead to
comparable P. aeruginosa growth and virulence in EVPL
Various formulations of artificial CF sputum media have been pub-
lished [20–23]. Here we focus on two formulations, which we term ASM1
and ASM2. ASM1 is the original formula we chose for use with the EVPL
model [33,34,51,52] and ASM2 is an updated version that has since been
published by the same laboratory [23]. ASM1 contains concentrations of
free amino acids, cations, anions and lactate that are representative of the4average concentrations found in a selection of sputum samples from
people with CF. ASM1 was initially chosen for use with EVPL as it was
shown to cue comparable carbon-usage pathways and expression of
quorum sensing signals by P. aeruginosa PA14 to growth in mediummade
from lyophilisedpatient sputum[22].ASM2addsbovinemaxillarymucin,
membrane lipid 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC),
N-acetyl glucosamine (NAG) and free DNA. These additions weremade to
better represent the presence of hostmucins, bacterialmembrane andwall
components, and the extracellular DNA (eDNA) found in the biofilm plugs
formed in the bronchioles of people with CF. ASM2 has been shown to
result in a comparable essential genome for P. aeruginosa PA14 to
lyophilised patient sputum media in vitro [23]. We aimed to determine
whether the EVPL model required the more complex ASM2, or whether
EVPL þ ASM1 would provide a sufficient platform for laboratory growth
of P. aeruginosa with more clinically realistic characteristics.
In our previous work with EVPL, we removed glucose from the
original ASM1 formulation as it appeared to enhance the growth of
endogenous bacteria from the porcine lungs [34]. We have tested the
effects of glucose removal from both versions of ASM on P. aeruginosa
growth and biofilm formation in vitro (Fig. S1). Our results show small
and inconsistent effects of ASM version and glucose removal on PA14 and
two clinical CF isolates. The limited effect of glucose removal is consis-
tent with the expectation that P. aeruginosa growth in the CF lung envi-
ronment mostly depends on using amino acids and short-chain fatty acids
as carbon sources [22,23,53,54]. Hence ASM without glucose is an
appropriate approach for use with EVPL, so glucose was omitted from
ASM for all further work.
Our previous work also showed typical morphology of P. aeruginosa
growing as extensive biofilms on EVPL þ ASM1 4 d post-infection (PI)
[33]. We have now further investigated the effect of ASM version on
growth and virulence in EVPL. P. aeruginosa PA14 and clinical isolates
SED42 and SED43 were used to infect EVPL with either ASM1 or ASM2,
and biofilm was recovered 2 d PI. The biofilm load did not differ between
EVPL þ ASM1 and EVPL þ ASM2 for PA14 or the exemplar clinical
isolates (Fig. 1A). To confirm that ASM version did not impact on other
aspects of P. aeruginosa biology, we measured the production of a se-
lection of exoproducts associated with virulence: the quorum sensing
signals C4-HSL and 3-oxo-C12 HSL, total protease and the siderophores
pyoverdine and pyochelin (Fig. 1B). ANOVAs confirmed that there was
not a significant effect of ASM version on any of these variables, as either
a main effect or interaction with strain (Table 2). Principal component
analysis did not reveal any clear clustering of phenotypes by ASM version
(Fig. S2). We also found that EVPL þ ASM1 was able to maintain
extended P. aeruginosa growth over 14 d (Fig. S3), with detectable
amounts of eDNA present in the biofilms formed 7 d PI (Fig. S4). It is not
clear whether this results from bacterial lysis or host cell damage, but as
the purD- mutant grows well in the presence of lung tissue it is likely that
a proportion of this eDNA is tissue-derived. These results indicate the
addition of EVPL removes the requirement of further additions made to
ASM1 in the form of ASM2, and enhances the suitability of the simpler
artificial media to mimic CF infection.
EVPL removes the essentiality of purine biosynthesis for P. aeruginosa
growth in both simple and complex formulations of ASM
To further confirm the optimal ASM version for use in all subsequent
work, and the effect on P. aeruginosa of adding EVPL tissue to ASM, we
compared one key aspect of primary metabolism in EVPL þ ASM1 and
EVPL þ ASM2. Purine biosynthesis was selected as it was previously
found to be essential in ASM2 in vitro but not in sputum taken from
people with CF [23]. This lack of consistency with true infection high-
lights a specific area where the composition of ASM2 appears
sub-optimal as a model for CF.
To confirm this previous finding, we performed in vitro growth curves
in ASM1 and ASM2 of the laboratory strain wild type (WT) P. aeruginosa
PA14 and a PA14 transposon insertion mutant for the purine auxotroph
Fig. 1. (A) Growth of the laboratory isolate Pseudomonas aeruginosa PA14 and two exemplar P. aeruginosa Cystic Fibrosis (CF) isolates: SED42 and SED43, on four
pieces of ex vivo pig lung (EVPL) bronchiole plus either artificial sputum media 1 (ASM1) (closed circles) or ASM2 (open circles). The colony forming units (CFU) were
retrieved from biofilm after 2 d growth. Bars denote means per ASM version. Strains varied in their biofilm load (ANOVA: F1,18 ¼ 3.64, p ¼ 0.047), but it was not
affected by ASM version (main effect F1,18 ¼ 0.84, p ¼ 0.37; interaction with strain F2,18 ¼ 0.01, p ¼ 0.99). Results were unaffected if the outlier in PA14 þ ASM1 was
excluded (p-values of 0.002, 0.70 and 0.64, respectively). (B) Production of selected virulence factors by P. aeruginosa isolates in EVPL þ ASM1 (closed circles) or
EVPL þ ASM2 (open circles). Bars denote means per ASM version. Units are as follows: for C4-HSL and 3-oxo-C12-HSL, Relative Light Units (RLU) of Escherichia coli
biosensor per CFU of P. aeruginosa; for total protease, A400 following azocasein assay per CFU of P. aeruginosa; for pyoverdine and pyochelin, fluorescence per CFU of
P. aeruginosa individually and as a ratio.
Table 2
Results of ANOVAs for the data shown in Fig. 1B. None of the analyses show a
significant effect of ASM version, either as a main effect or as an interaction with
strain. Raw data and R code are provided in the Data Supplement.
Strain ASM Strain*ASM
F2,18 p F1,18 p F2,18 p
C4-HSL 6.00 0.011* 2.27 0.150 1.86 0.185
3-oxo-C12-HSL 1.41 0.342 0.49 0.493 0.35 0.709
Total protease 2.07 0.155 0.37 0.553 0.95 0.406
Pyoverdine (PVD) 2.07 0.155 0.37 0.553 0.95 0.406
Pyochelin (PCH) 2.14 0.147 0.65 0.430 0.89 0.429
PVD/PCH 0.25 0.781 0.26 0.619 0.28 0.758
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5gene purD. We also measured growth of two isogenic mutants auxotro-
phic for amino acids abundant in ASM: leuB and metX, as positive con-
trols. We found that in both versions of ASM purine supplementation is
required for purD mutant growth in vitro (Fig. 2A).
To identify whether the presence of EVPL could compensate for this
shortcoming we infected two independent lungs with the four
P. aeruginosa PA14 strains used in vitro (WT; purD, leuB andmetXmutants).
Bacterial growth was recovered at 2 d PI to determine CFU per lung
(Fig. 2B). This was repeated using either ASM1 or ASM2 with the EVPL.
Fig. 2B highlights the consistency in CFU per lung of the WT between
EVPLþ ASM1 and EVPLþ ASM2. Statistical analysis found no significant
difference in CFU between any individual mutant and theWT in the same
Fig. 2. (A) Growth of Pseudomonas aeruginosa PA14 and transposon insertion metabolic mutants in vitro in artificial sputum media 1 (ASM1) (solid) and ASM2
(dashed). Black lines are ASM alone, blue lines show ASM cultures supplemented with 20 μg ml1 leucine, 20 μg ml1 methionine or 30 μg ml1 each of purines
(guanine, adenine, xanthine and hypoxanthine) as appropriate. All treatments were replicated in triplicate and lines show individual replica cultures. (B) Growth of
P. aeruginosa PA14 and transposon insertion metabolic mutants on three pieces of ex vivo pig lung (EVPL) bronchiole from each of two independent lungs (circles vs.
squares) plus ASM1 (closed symbols) or ASM2 (open symbols). The graph shows colony-forming units (CFU) retrieved from individual EVPL biofilms after 48 h
growth. The bars denote means per ASM version. An ANOVA was run to test for effects of lung identity, genotype, version of ASM used and the interaction between
genotype and version of ASM used, on biofilm load. One clear outlier (purD-, ASM2, denoted with a star) was identified and excluded from analysis of this data. There
was no main effect of lung identity or genotype on biofilm load (ANOVA: F3,38 ¼ 0.56, p ¼ 0.448 and F1,38 ¼ 0.46, p ¼ 0.712). Biofilm load was affected by the version
of ASM used (main effect F1,38 ¼ 12.1, p ¼ 0.001; interaction with genotype F3,38 ¼ 3.50, p ¼ 0.024). A Tukey test showed statistical interaction was driven by the
purDmutant (p < 0.01). Planned contrasts by conducting t-tests where t ¼ (mutant CFU –WT CFU in the same medium)/SEdiff, where SEdiff is the standard error of the
difference, calculated using the residual mean square from the ANOVA, showed no significant difference in CFU between individual mutants and WT in the same
version of ASM (2-tailed p  0.126). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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reduction in bacterial load compared with the WT in the corresponding
ASM version. It can be concluded that addition of EVPL removes the es-
sentiality of purine biosynthesis in ASM1, making it consistent with clin-
ical infection. It is alsoworthnoting that the slight growthdefect of theWT
observed in ASM1 in vitro compared to ASM2 (Fig. 2A) is not observable
when EVPL is added (Fig. 2B).
In conclusion, there does not appear to be any significant differences
in P. aeruginosa growth, virulence or purine metabolism in EVPLþ ASM1
and EVPL þ ASM2. We therefore used EVPL þ ASM1 to explore the ar-
chitecture of P. aeruginosa biofilms formed.P. aeruginosa biofilm formation on EVPL with ASM recapitulates the
morphology of in vivo CF biofilms, and is dependent on the Gac regulatory
system and Pel polysaccharide
Biofilm formation is arguably the defining phenotype of chronic
P. aeruginosa lung infection in individuals with CF. Following6identification of optimal EVPL model conditions, we explored the struc-
ture and mechanisms of biofilm formation by P. aeruginosa PA14 on EVPL
þ ASM1. Initially, we confirmed that we were observing PA14 growth in
the model and not simply maintaining inoculation CFU by measuring
growth across 7 days in two independent lungs, and in ASM1 in vitro.
Similar growth curveswere obtained in lungs andASM1 (Fig. S5).We then
compared the biofilm formed by WT PA14 with those formed by trans-
poson insertion mutants for the genes gacA and pelA. Both gacA and pelA
are important in biofilm infection by P. aeruginosa PA14; either by direct
regulation (gacA) or production of a structural matrix polysaccharide
(pelA). GacA is a response regulator from the global activator of antibiotic
and cyanide synthesis (Gac) two-component regulatory system. The Gac
system is well-studied and known to be largely responsible for the switch
from acute to chronic infection; in particular it regulates biofilm matura-
tion [55,56]. PelA is a periplasmic protein required for biosynthesis of the
biofilm matrix exopolysaccharide Pel. It is one of three exopoly-
saccharides associated with P. aeruginosa biofilm formation: Pel, Psl and
alginate. In PA14, alginate is non-essential for biofilm formation andPA14
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exopolysaccharide. Pel-deficient mutants have been shown to arrest in an
early stage of biofilmdevelopment, forming thin,flatmonolayers [41,57].
To investigate biofilm formation by P. aeruginosa PA14 WT and the
gacA and pelA mutants, strains were inoculated individually into replica
lung pieces from three independent lungs. Uninfected tissue was used as
the negative control. We recovered the biofilm at 2 d and 7 d PI to
determine CFU per EVPL section across an extended time period
(Fig. 3A). ANOVAs identified a significant difference in CFU per EVPL
tissue section between both the gacA and pelA mutants and the WT at 2
d PI (Fig. 3A). However, there was only a significant difference in CFU
per EVPL section between the gacA mutant and WT 7 d PI (Fig. 3A). The
interaction term between replicate lungs and infection strain was found
to be significant, reflecting the natural variation between lungs rather
than true differences in WT and mutant growth. This is not dissimilar to
the patient-to-patient variation expected clinically.Fig. 3. (A, B) Colony forming units (CFU) per ex vivo pig lung (EVPL) bronchiolar
transposon mutants at (A) 2 d and (B) 7 d post-infection (PI). Five replicate pieces of ti
each genotype across all three lungs, and asterisks denote a significant difference fro
found a significant difference between strains, lung and their interaction at 2 d PI (stra
P ¼ 0.06). Post-hoc analysis showed that there was significantly higher CFU recover
mutant than the WT (P ¼ 0.01). At 7 d PI a significant difference in bacterial recovery
between strain and lung (ANOVA: strain F4,60 ¼ 5.40, P < 0.01; lung F2,60 ¼ 78.98,
difference in CFU per lung between the WT and pelA mutant (P ¼ 0.69). A significan
0.047) 7 d PI. (C) Micrographs of Gram-stained PA14 WT and selected transposon m
7Gram staining confirmed that the uninfected tissue was clear of
bacterial growth at 2 d and 7 d PI (data not shown). Aggregates of Gram-
negative rods were visible on the surface of EVPL tissue infected with
each strain at both time points (Fig. 3B). The Gram stain images also
demonstrate the increase in density of bacterial cells from 2 d PI to 7 d PI
for both mutants and the WT.
H & E staining is a histological technique traditionally used to visu-
alise mammalian tissue architecture. However there are a number of
studies that have adopted this technique to detect biofilms associated
with host tissue for use as a clinical diagnostic tool [58–61]. Although it
is a non-specific stain that cannot distinguish between different bacterial
species, when performed alongside Gram staining (Fig. 3C), it is a quick,
cost-effective approach to detect bacteria, their biofilms and the structure
of associatedmammalian tissue. It has been reported as a reliable method
for biofilm staining by cross-referencing H & E stained tissue sections
with sections imaged using fluorescence in situ hybridisation (FISH) andtissue section infected with Pseudomonas aeruginosa PA14 wild type (WT) and
ssue were infected per strain from three independent lungs. Bars denote mean for
m the WT under that condition (post-hoc Dunnett’s test after ANOVA). ANOVA
in F4,60 ¼ 10.27, P < 0.01; lung F2,60 ¼ 26.05, P < 0.01; interaction F8,60 ¼ 1.99,
ed of the gacA mutant compared to the WT (P < 0.01), and higher CFU of pelA
was found between strains and between lungs, as well as a significant interaction
P < 0.01; interaction F8,60 ¼ 2.01, P ¼ 0.06). There was no longer a significant
tly greater CFU per lung was recovered from the gacA mutant than the WT (P ¼
utants in EVPL þ ASM1 at 2 d and 7 d PI. All images are x100 magnification.
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crystal violet biofilm assay is not suitable for use on ex vivo tissue sam-
ples. As shown in Fig. S6A, the lung tissue preferentially binds crystal
violet obscuring any signal from dye bound to the biofilm matrix. A
similar issue was found with the Congo red binding assay for Pel pro-
duction (Fig. S6B). Hence, H & E staining was used to visualise the
P. aeruginosa biofilms on EVPL tissue as it stains both the bacteria and
extracellular polymeric substances of the biofilm, as well as the porcine
tissue. Alcian blue staining was also performed as a standard technique
for identifying the biofilm matrix [16,62,63]. Replica sets of infected
lung pieces from two independent lungs were fixed at 2 d PI and 7 d PI
and sections stained with either Gram strain to identify bacteria (Fig. 3C),
Alcian blue to stain the biofilm polysaccharide matrix (Fig. 4A–D), or H&
E to visualise the total biofilm mass and tissue architecture (Fig. 4E-L).
H&E images for each strain at 7 d PI are shown in Fig. 4: the basophilic
bacteria andbiofilmmatrix are stainedpurple by the hematoxylin, and the
connective tissue of the bronchiole is stained pink by the eosin (replicate
images from a second lung are provided in Fig. S7). Whilst Gram stain
images identified Gram-negative rods present 2 d and 7 d PI (Fig. 3C), H&
E staining gave a clear image of all aspects of the EVPL biofilmmodel: the
tissue, bacteria and biofilm matrix. A diagram explaining each aspect of
the tissue and the biofilm evident in the H& E images is shown in Fig. S8.
This was further complementedwith Alcian blue staining (Fig. 4) showing
the biofilm matrix associated with the tissue.Fig. 4. Sections of ex vivo pig lung (EVPL) bronchiolar tissue with artificial sputum m
EVPL was infected with Pseudomonas aeruginosa PA14 wild type (WT) and selected PA
blue stained sections counterstained with nuclear fast red. The biofilm matrix is stain
and eosin (H & E) stained sections. The cartilage and tissue surface (red bar) stain pi
biofilm matrix. A detailed diagram of the biofilm structure as shown by H & E stainin
are taken from the same section as shown in x20 (denoted by the dashed boxes). The
magnification images. (For interpretation of the references to colour in this figure le
8There were clear qualitative differences in the biofilm observed be-
tween the mutant strains andWT 7 d PI using Alcian blue (Fig. 4A–D) and
H & E staining (Fig. 4E-L). As shown in Fig. 4F,J the WT formed a thick
structure on the surface of the tissue, comprising of layers of bacteria and
matrix punctuated with spaces, comparable to CF biofilms observed in
vivo using H & E or Alcian blue staining (see Figure 4 in Ref. [16] and
Figure 8 in Ref. [29]). Alcian blue staining confirmed the spaces are truly
open with a comparable structure visible in the blue stained WT biofilm
(Fig. 4B), indicating there is no matrix polysaccharide occupying the
empty space visualised with H & E staining. This structure was not pre-
sent in the biofilm formed by the gacA mutant: the purple stained region
on the surface of the EVPL tissue demonstrates the homogenous, dense
biofilm matrix formed by the gacA mutant (Fig. 4G,K). It was supported
by dense Alcian blue staining of the biofilm matrix (Fig. 4C) compared to
theWT (Fig. 4B). Images of the pelAmutant biofilm are comparable to the
uninfected tissue: we identified only a thin layer of purple stain at 7 d PI
(Fig. 4H,L). Although the pelA mutant was able to grow on EVPL tissue
(Fig. 3), it was unable to form a biofilm. There was evidence of aspects of
a biofilm matrix produced by the pelA mutant on the Alcian blue images
(Fig. 4D). This is consistent with work on PA14 in in vitro biofilm systems,
in which pelA mutants can attach to a surface to form a thin monolayer,
but do not develop further into biofilms reminiscent of the WT [41].
Biofilm depth measurements taken from the images are provided in
Fig. S10, supporting visual findings. At 2 d PI, these differences althoughedia 1 (ASM1) infected with Pseudomonas aeruginosa at 7 d post infection (PI).
14 transposon mutants, with uninfected tissue as a negative control. (A–D) Alcian
ed blue and the EVPL tissue and cartilage stained red/pink. (E–L) Hematoxylin
nk and the bacterial biofilm (black bar) purple, including the bacterial cells and
g is provided in the supplementary information. The x100 magnification images
P. aeruginosa rods are visible, which make up the structures evident in the lower
gend, the reader is referred to the Web version of this article.)
N.E. Harrington et al. Biofilm 2 (2020) 100024visible were not as clearly defined with Alcian blue or H & E staining
(Fig. S9).
The difference between WT growth and mutants associated with
pathways known to be essential for biofilm matrix production (Pel
polysaccharide) and biofilm maturation (GacAS regulatory system)
confirmed that the structures formed by P. aeruginosa PA14 on the surface
of EVPLþ ASM1 are biofilm. Comparison with published images from CF
lung biopsies show that the biofilm structure of PA14 WT on EVPL is in
vivo-like.
Discussion
CF can dramatically impact an individual’s quality of life and has a
high mortality rate. Alongside this, the condition also has a major impact
on healthcare systems worldwide. Throughout their lifetime people with
CF continually require treatment for lung infections. In the US, the esti-
mated median annual costs for treatment of pulmonary exacerbations, a
period of acute-like infection that is highly virulent, ranges from $9,456
(USD) to $48,263 (USD) per person [64]. There is a limited choice of
effective antibiotics to treat CF lung infections currently available to
clinicians, and the antibiotic tolerance observed in vivo means that
standard antibiotic susceptibility testing does not accurately predict
whether drugs will actually work [17,18]. As individuals with CF are
living longer, there is a growing medical and economic need for novel
and improved treatments for lung infections that are more effective and
less rigorous. The rising incidence of antimicrobial resistance (AMR) is
only adding to this pressure. Prescribing cannot be improved, nor can a
true insight into the impact of potential novel treatment agents (e.g.
anti-virulence drugs) be achieved, until there is a better understanding of
the fundamental microbiology underpinning these chronic biofilm in-
fections. We aimed to develop a clinically-relevant ex vivo model for the
predominant cause of chronic CF lung infections: P. aeruginosa. We have
demonstrated that addition of EVPL tissue to a simple formulation of
ASM results in a clinically realistic P. aeruginosa biofilm, overcoming a
number of obstacles associated with current laboratory models of CF
infection.
We initially aimed to define the optimal P. aeruginosa culture condi-
tions for the EVPL model to ensure we are closely modelling clinical CF
lung infections. Investigation of P. aeruginosa growth, virulence and pu-
rine biosynthesis showed that addition of the porcine bronchiolar tissue
overcomes issues associated with in vitro growth in the laboratory media
ASM1 and ASM2.
ASM1 is simpler and cheaper to make than ASM2, thus our conclusion
that ASM1 is sufficiently realistic when used with EVPLmakes the system
readily accessible and tractable for use in research and potentially
diagnostic laboratories. It is plausible that ASM1 is sufficient with the
addition of EVPL for two primary reasons. Firstly, mucin is unlikely to be
an important physiological cue in vivo and in EVPL as it is a poorly used
carbon source for P. aeruginosa [54,65]. In vitro it is likely that mucin acts
as a structural cue for P. aeruginosa aggregation and the switch to biofilm
lifestyle, however we observed biofilm formation on EVPL in the absence
of exogenous mucin. Additionally, the prolonged growth periods and
high biofilm densities possible with EVPLmean it is likely that membrane
lipids, NAG and eDNAwill be released from cells within the tissue and/or
maturing biofilm. Our findings suggest that EVPL tissue with ASM1
provides key compounds that are lacking from the media alone, creating
a closer match with authentic sputum from people with CF.
Visualisation of the biofilm is key to comparing laboratory models
with in vivo biofilms. We used H & E staining as this stains both the EVPL
tissue and the bacterial cells [58,60], which is not possible with other
more bacteria specific microscopy techniques. This allowed us to detect
the formation of a biofilm and its location on the tissue, as well as any
potential tissue damage. This approach is relatively simple to perform
and cost-effective [58,59], thus beneficial to address our aim of detecting
the biofilm visualising its structure using approaches that will make the
model tractable for diagnostics where time and cost savings are9necessary. We also performed Alcian blue staining to visualise the biofilm
matrix [16,63] to confirm the H & E images, which supported our
conclusions.
However, unlike techniques such as FISH, H & E staining does not
provide taxonomic bacterial identification [58]. It is suitable for work
focusing on mono-species biofilm, in which we know the species we have
introduced. More specific approaches must be used in work focused on
polymicrobial biofilms. Our confirmatory work using H & E and
P. aeruginosa paves the way for the use of EVPL to conduct more complex
microscopic analysis of single and mixed-species lung biofilms using
FISH or scanning electron microscopy to gain further insight into
infection.
We found that the laboratory P. aeruginosa strain PA14 forms a bio-
film on the surface of EVPL tissue, with a lace-like structure of bacterial
aggregates surrounding air or fluid spaces. On a structural level it is
comparable to P. aeruginosa biofilms that have been observed in
explanted lung tissue from people with CF (see Figure 8 in Ref. [29],
Figure 4 in Ref. [30] and Figure 4 in Ref. [16]). The EVPL biofilm appears
more structurally heterogeneous than has been previously observed in
vitro [28], and distinct from the “mushroom” type typically seen in flow
cell biofilms (see Figure 8 in Ref. [2]). Our findings support the conclu-
sion that EVPLmimics a clinically realistic P. aeruginosa biofilm infection.
The porcine tissue provides the structure and physiological cues that
facilitate the formation of biofilms representative of CF infection.
To explore the mechanisms responsible for biofilm formation in the
EVPL model, we also imaged the biofilm formed by two PA14 transposon
mutants: pelA and gacA. We identified clear differences in growth in
EVPL. The pelA gene encodes a deacetylase and hydrolase enzyme
involved in the synthesis of the biofilm exopolysaccharide pellicle: Pel
[57]. Previous studies have shown that the Pel polysaccharide is neces-
sary for cell-cell interactions and development of P. aeruginosa PA14
biofilms [41]. This is consistent with our images showing that the pelA
mutant was unable to form a biofilm on the surface of the EVPL bron-
chiolar tissue. Interestingly, whilst the pelA mutant formed visually less
biofilm than the WT, similar CFU were recovered from tissues infected by
both genotypes. This may suggest that a large portion of cells visible in
WT biofilms are dead or viable but not culturable. Alcian blue stained the
bacterial biofilm on the surface of the tissue infected with the pelA
mutant 7 d PI. As the mutant is Pel-deficient and PA14 is Psl-deficient,
this is likely to be staining of lipopolysaccharide and/or alginate. The
presence of alginate could explain the mutant’s ability to attach to the
tissue surface despite being unable to form a biofilm.
The gacA mutant however was found to form a biofilm, but it lacked
the structure that was observed for the WT by H & E staining. This was
similarly observed with Alcian blue staining, and the biofilm matrix
components appeared to be densely packed in comparison to the WT.
GacA has been shown to be essential for P. aeruginosa PA14 biofilm
maturation, and lack of gacA function results in a reduction in biofilm
formation capacity and structure, and reduced antibiotic resistance [55].
The development of the WT biofilm architecture is dependent on the
GacAS system so may be considered a “mature” state. Our observations
thus confirm the importance of established biofilm regulatory pathways
in the formation of the structured communities observed on EVPL tissue.
This supports the conclusion that P. aeruginosa is forming a mature bio-
film in the EVPL model.
Further analysis of EVPL infection at a genotypic level will be
required to fully conclude which aspects of chronic CF infection dy-
namics the model is able to recapitulate. However, we present EVPL þ
ASM1 as a cheap, tractable and high-throughput platform for growing
P. aeruginosa biofilms. The EVPL infections we observed exhibit some of
the key morphological and metabolic characteristics observed for this
pathogen in CF. Our results clearly demonstrate the importance of vis-
ualising biofilms grown in laboratory models. When we compared the
CFU per lung of WT, pelA and gacA mutants, there were no clear differ-
ences in bacterial recovery – but there were obvious differences in the
structure of the biofilms they formed. Visualisation of biofilms formed on
N.E. Harrington et al. Biofilm 2 (2020) 100024EVPL tissue are a valuable addition to future work, with the aim to un-
derstand infection dynamics, antibiotic tolerance, polymicrobial in-
teractions and the ability of novel drugs to penetrate and destroy these
biofilms.
Conclusions
We have shown, in extension to our previous work [30,31], that the
EVPL model is able to successfully replicate a phenotypically realistic
P. aeruginosa CF lung biofilm. Our work can now be expanded to further
understanding of other key aspects of infection, as well as a basis for
development of ex vivo models for other biofilm infection contexts. The
model provides a high-throughput approach to bridge the gap between in
vitro models and true human infection.
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